<p>Vincenzo Casolaro of the University of Maryland School of Medicine in the United States will test the ability of a novel synthetic peptide, AT1002, to induce the pathways within the mucosa to increase the delivery of antigens. If successful, this peptide could be used as an adjuvant to increase vaccine effectiveness and lower the costs of delivering vaccines.</p>


Vincenzo Casolaro of the University of Maryland School of Medicine in the United States will test the ability of a novel synthetic peptide, AT1002, to induce the pathways within the mucosa to increase the delivery of antigens. If successful, this peptide could be used as an adjuvant to increase vaccine effectiveness and lower the costs of delivering vaccines.